Predicting bladder cancer risk in patients with hematuria. A single-centre retrospective study

Published: March 15, 2023
Abstract Views: 953
PDF: 459
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Introduction: The presence of blood in the urine should be promptly investigated to rule out urological malignancies, bladder cancer being the most frequent. Given its frequency among general population and the lack of unlimited health resources in an era of cost-effectiveness, it is important to prioritize patients with higher risk of malignancy.

Objectives: To identify predictive factors of bladder cancer among patients presenting with hematuria.
Patients and Methods: We retrospectively reviewed 296 cases referred to our department for hematuria. We evaluated different demographic, clinical and ultrasound features to uncover possible associations with diagnosis of bladder cancer in those patients, to estimate the individual risk of being diagnosed with bladder cancer during the investigation of hematuria.

Results: A total of 296 patients were studied for hematuria between January 1, 2017 and December 31, 2019, 23.6% of those having ultimately bladder cancer confirmed after transurethral resection. Older age, male gender (OR 2.727, p = 0.069), a history of smoking (OR 3.84, p < 0.05), recurrent hematuria (OR 3.396, p < 0.05) and positive ultrasound exam for bladder cancer (OR 30.423, p < 0.05) were identified as predictors of bladder cancer in patients with hematuria.

Conclusions: This study suggests that it is possible to reliably estimate the risk of bladder cancer in patients with hematuria, using clinical and imaging data to help defining who should be investigated first and in whom the investigation could be postponed.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Tan WS, Feber A, Sarpong R, et al. Who Should Be Investigated for Haematuria? Results of a Contemporary Prospective Observational Study of 3556 Patients. Eur Urol. 2018; 74:10-4. DOI: https://doi.org/10.1016/j.eururo.2018.03.008
National Collaborating Centre for Cancer (UK). Suspected Cancer: Recognition and Referral. London: National Institute for Health and Care Excellence (NICE); 2015 Jun.
Banks J, Hollinghurst S, Bigwood L, et al. Preferences for cancer investigation: a vignette-based study of primary-care attendees. Lancet Oncol. 2014; 15:232-40. DOI: https://doi.org/10.1016/S1470-2045(13)70588-6
Davis R, Jones JS, Barocas DA, et al. American Urological Association. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol. 2012; 188 (6 Suppl):2473-81. DOI: https://doi.org/10.1016/j.juro.2012.09.078
Malmström P-U. Time to abandon testing for microscopic haema- turia in adults? BMJ. 2003; 326:813-5. DOI: https://doi.org/10.1136/bmj.326.7393.813

How to Cite

Jarimba, R., Quaresma , V., Pedroso Lima, J., Eliseu, M., Tavares da Silva, E., Moreira, P., & Figueiredo, A. (2023). Predicting bladder cancer risk in patients with hematuria. A single-centre retrospective study. Archivio Italiano Di Urologia E Andrologia, 95(1). https://doi.org/10.4081/aiua.2023.11026